VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer
Cancers · 17.04.2023 · 15 (8) · 2326
DOI: 10.3390/cancers15082326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 17.04.2023. Verfasst von David Digomann und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Visceral, Thoracic and Vascular Surgery, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden,…. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Else Kröner-Fresenius-Stiftung, Jung Stiftung.
Abstract (Originalsprache)
Immunotherapy has shown promising results in multiple solid tumors and hematological malignancies. However, pancreatic ductal adenocarcinoma (PDAC) has been largely refractory to current clinical immunotherapies. The V-domain Ig suppressor of T-cell activation (VISTA) inhibits T-cell effector function and maintains peripheral tolerance. Here, we determine VISTA expression in nontumorous pancreatic (n = 5) and PDAC tissue using immunohistochemistry (n = 76) and multiplex immunofluorescence staining (n = 67). Additionally, VISTA expression on tumor-infiltrating immune cells and matched blood samples (n = 13) was measured with multicolor flow cytometry. Further, the effect of recombinant VISTA on T-cell activation was investigated in vitro, and VISTA blockade was tested in an orthotopic PDAC mouse model in vivo. PDAC showed significantly higher VISTA expression compared to that of a nontumorous pancreas. Patients with a high density of VISTA-expressing tumor cells had reduced overall survival. The VISTA expression of CD4+ and CD8+ T cells was increased after stimulation and particularly after a coculture with tumor cells. We detected a higher level of proinflammatory cytokine (TNFα and IFNγ) expression by CD4+ and CD8+ T cells, which was reversed with the addition of recombinant VISTA. A VISTA blockade reduced tumor weights in vivo. The VISTA expression of tumor cells has clinical relevance, and its blockade may be a promising immunotherapeutic strategy for PDAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Visceral, Thoracic and Vascular Surgery, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
- National Center for Tumor Diseases (NCT/UCC), 01307 Dresden, Germany.
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
- Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany.
- Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
ORCID-Profile: David Digomann, Max Heiduk, Luise Rupp, Adrian M Seifert, Lena Seifert
Förderung
- Deutsche Forschungsgemeinschaft
- Else Kröner-Fresenius-Stiftung
- Jung Stiftung
- Monika Kutzner Stiftung
- The Else Kröner-Fresenius-Stiftung
- The Ernst-Jung Stiftung
- The Monika Kutzner Stiftung
- The German Research Foundation
Zitieren
APA
Digomann, D., Strack, J., Heiduk, M., Plesca, I., Rupp, L., Reiche, C., Nicolaus, S., Beer, C., Sommer, U., Schmitz, M., Distler, M., Weitz, J., Seifert, A. M., & Seifert, L. (2023). VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer. Cancers, 15(8), 2326. https://doi.org/10.3390/cancers15082326
Vancouver
Digomann D, Strack J, Heiduk M, Plesca I, Rupp L, Reiche C, et al. VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer. Cancers. 2023;15(8):2326. doi:10.3390/cancers15082326
BibTeX
@article{Digomann2023,
author = {Digomann, David and Strack, Johannes and Heiduk, Max and Plesca, Ioana and Rupp, Luise and Reiche, Charlotte and Nicolaus, Simone and Beer, Carolin and Sommer, Ulrich and Schmitz, Marc and Distler, Marius and Weitz, Jürgen and Seifert, Adrian M and Seifert, Lena},
title = {VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer},
journal = {Cancers},
year = {2023},
volume = {15},
number = {8},
pages = {2326},
doi = {10.3390/cancers15082326}
}
EUVIMED